PMEL and melanoma: The trial that led to registration of ipilimumab in melanoma was a phase III trial in which ipilimumab ± glycoprotein 100 peptide (gp100) vaccine was compared with gp100 vaccine monotherapy in patients with unresectable stage III or stage IV melanoma.